iOUTRUN: Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients Read more about iOUTRUN: Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
Real-World Experience of Upadacitinib in Moderate to Severe Atopic Dermatitis Read more about Real-World Experience of Upadacitinib in Moderate to Severe Atopic Dermatitis
Use of high dose of Colistin in Multidrug Resistant Gram Negative infections. Randomized Controlled clinical Trial Read more about Use of high dose of Colistin in Multidrug Resistant Gram Negative infections. Randomized Controlled clinical Trial
"easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment" Read more about "easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment"
"AN OBSERVATIONAL, NON-INTERVENTIONAL,MULTI-CENTER, MULTI-NATIONAL STUDY OFPATIENTS WITH ATYPICAL HEMOLYTIC-UREMICSYNDROME(AHUS REGISTRY)" Read more about "AN OBSERVATIONAL, NON-INTERVENTIONAL,MULTI-CENTER, MULTI-NATIONAL STUDY OFPATIENTS WITH ATYPICAL HEMOLYTIC-UREMICSYNDROME(AHUS REGISTRY)"
A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome Read more about A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Dexaflox Eye Drops Containing Ofloxacin (3 mg) and dexamethasone (1 mg) in Subjects with Bacterial Conjunctivitis Read more about An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Dexaflox Eye Drops Containing Ofloxacin (3 mg) and dexamethasone (1 mg) in Subjects with Bacterial Conjunctivitis
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctivitis and Other Ocular Inflammatory Conditions Read more about An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctivitis and Other Ocular Inflammatory Conditions
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Fluca Eye Drops Containing Sodium Cromoglycate (20 mg/ml) and Fluorometholone (1 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever Read more about An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Fluca Eye Drops Containing Sodium Cromoglycate (20 mg/ml) and Fluorometholone (1 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever
An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever (Seasonal) Read more about An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever (Seasonal)